Semax Peptide Structure: How the ACTH(4-10) Heptapeptide Is Designed

Some peptides are designed from scratch. Semax isn't one of them. It began as a slice of a hormone the body already makes, and its whole identity comes down to a single deliberate edit at the tail end of that slice. If you're trying to understand how researchers turn a natural sequence into a sturdier, more useful research compound, Semax is about as clean an example as you'll find. One note before we dig in: Semax is sold and studied for research use only, and nothing here describes human use — this is a look at chemistry and published research, not a guide to anything else.

We'll start with the parent fragment, ACTH(4-10), then read the Semax sequence one residue at a time, explain why a Pro-Gly-Pro tail was engineered onto the end, and finish with what laboratory studies have observed about how the molecule works and how it eventually comes apart.

What ACTH(4-10) Is, and Where Semax Comes From

The short version: Semax is a redesigned piece of a stress hormone. That hormone is adrenocorticotropic hormone, or ACTH — a 39-residue signal best known for telling the adrenal glands to release cortisol. Decades ago, though, researchers noticed that a small internal stretch of ACTH, the region covering residues 4 through 10, carried interesting brain activity that had little to do with the hormone's day job.

That stretch, ACTH(4-10), reads Met-Glu-His-Phe-Arg-Trp-Gly. Building from a fragment rather than a whole hormone is a recurring move in peptide science — the same logic drives a fragment of a larger hormone like Sermorelin, which keeps the active front of growth-hormone-releasing hormone and drops the rest. The bet never changes: if a short piece does the interesting work, you can build something smaller and more manageable around it.

Semax takes that bet. It holds onto the first four residues of ACTH(4-10) — Met-Glu-His-Phe, positions 4 through 7 of ACTH — and replaces the native tail. Researchers describe the result as a hybrid molecule carrying an ACTH(4-7) fragment joined to a Pro-Gly-Pro tripeptide, built specifically for better resistance to enzymatic breakdown (PMC: Alzheimer's model study). That swap — losing Arg-Trp-Gly, gaining Pro-Gly-Pro — is the whole story of how Semax differs from the natural fragment.

Reading the Sequence Residue by Residue

What does that section title mean in chemistry? Each letter in a peptide name is one amino acid, strung together in order from the start (the N-terminus) to the end (the C-terminus). Semax reads Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP in single-letter code. Seven amino acids make it a heptapeptide — and that count is literally where the name comes from, as we'll see in a moment.

The molecular formula is C₃₇H₅₁N₉O₁₀S, for a molar mass of about 813.93 g/mol (Wikipedia: Semax). That lone sulfur atom flags the methionine at the front; the rest is the carbon-nitrogen-oxygen scaffolding you'd expect from a chain of residues joined by the amide bonds that link each residue.

Walking the chain from the N-terminus:

• Met (methionine) — the N-terminal residue, source of the molecule's only sulfur.
• Glu (glutamate) — an acidic residue with a carboxylate side chain.
• His (histidine) — the imidazole-bearing residue that does the metal-binding work we'll come back to.
• Phe (phenylalanine) — a bulky aromatic residue closing out the ACTH-derived portion.
• Pro-Gly-Pro — the engineered tail: two prolines bracketing a glycine.

You'll see the compound under a few different names, all the same molecule: H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, or the more formal (Pro⁸,Gly⁹,Pro¹⁰)ACTH-(4-10), which spells out exactly which positions were substituted. The everyday name has a simpler origin. "Semax" comes from the Russian phrase for "seven amino acids" — a tidy nod to its heptapeptide makeup — and it was first described in the scientific literature in 1991.

Why Pro-Gly-Pro? Designing for Stability

The plain answer: the tail keeps enzymes from taking the molecule apart too fast. Short peptides have a chronic weakness. The body is full of peptidases — enzymes that snip peptide chains — and an unprotected fragment can disappear almost as quickly as it shows up. Anyone hoping to study a short sequence has to wrestle with that fragility first.

Proline is the clever part of the fix. Its ring-shaped side chain makes it an awkward, poorly-fitting substrate for many peptidases, so a proline parked at or near a chain's end tends to slow enzymatic attack. Capping the C-terminus with Pro-Gly-Pro gave Semax measurably better resistance to degradation and a longer working life than the bare fragment would have (PMC: copper-induced Aβ study). The Pro-Gly-Pro motif isn't decoration — it's a stability strategy written straight into the sequence.

Worth putting in context: a proline cap is just one of other strategies researchers use to extend a peptide's half-life. Attaching a fatty tail is a very different route to the same goal. Semax happens to solve the problem with geometry rather than added bulk.

The structure has a second feature worth flagging. Histidine, paired with the N-terminal methionine, lets Semax coordinate copper(II) ions and form a remarkably stable complex (a conditional dissociation constant around 1.3 × 10^-15 M). That copper-binding behavior has turned the molecule into a subject of interest in cell-culture work on metal-induced toxicity and amyloid aggregation — a property that falls right out of the same residues that define its structure.

How the Design Changes Activity vs the Native Fragment

So the tail protects the molecule. But does it change what the molecule does? Research suggests it does. In a comparative study set in rodent models, swapping the three C-terminal residues of ACTH(4-10) for Pro-Gly-Pro didn't just slow degradation — it augmented the analog's potency relative to the unmodified fragment (PubMed: comparative potency study). In those experiments, the Semax-style analog was active at substantially lower concentrations than the native sequence needed.

This is what "rational design" looks like in practice. The change wasn't a shot in the dark; it was a targeted edit to one end of a known-active sequence, and it produced a measurable, observed-in-research shift in how strongly the peptide behaved. For anyone learning how peptide chemists think, that's the takeaway — the terminus isn't just a stopping point, it's a design surface.

What the Structure Does: Mechanism in Research Terms

What does this molecule actually interact with? Honestly, the full picture is still being worked out, but research has mapped several pieces. One point up front: unlike its parent ACTH, Semax shows no hormonal activity. It behaves as a regulatory peptide rather than a hormone — part of why it drew research interest in the first place.

Because the molecule descends from ACTH, the melanocortin system is a natural place to look. Studies describe Semax acting as a competitive antagonist of alpha-melanocyte-stimulating hormone at the MC4 and MC5 melanocortin receptors. That receptor connection is one it shares, in spirit, with another melanocortin-system analog — though Melanotan II is built and behaves very differently.

Beyond those receptors, animal studies have reported rapid increases in brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus after exposure, and some work proposes that the peptide binds allosterically to receptors and subtly shifts their behavior (PMC: Alzheimer's model study). Every one of these findings is a research observation in cell-culture or animal models — not a statement about people — and that distinction matters throughout.

What Happens to Semax After Binding: Metabolic Fate

The last piece of the structural story is what the body's enzymes do with the molecule — and here the design pays off in a way you might not expect. In rat forebrain tissue, Semax binds plasma membranes in a specific, reversible, calcium-dependent manner, with an affinity constant (K_d) around 2.4 nM and a membrane half-life longer than an hour (PubMed: binding and biodegradation study).

When it does come apart, the process is orderly rather than random. Dipeptidylaminopeptidases trim the chain stepwise from the front: MEHFPGP first sheds residues to become the five-residue HFPGP, then the three-residue PGP. And that final fragment is itself a recognized regulatory peptide — so the Pro-Gly-Pro tail added for stability doesn't simply vanish when the parent molecule degrades. It leaves behind a small, biologically meaningful piece. The design choice echoes all the way through the molecule's lifecycle.

Frequently Asked Questions

What is the amino acid sequence of Semax?

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP in single-letter notation. Its molecular formula is C₃₇H₅₁N₉O₁₀S and its molar mass is about 813.93 g/mol. The first four residues (Met-Glu-His-Phe) are taken directly from positions 4–7 of adrenocorticotropic hormone, and the final three (Pro-Gly-Pro) are a synthetic addition.

How is Semax related to ACTH(4-10)?

Semax is a synthetic analog of ACTH(4-10), the fragment spanning amino acids 4 through 10 of adrenocorticotropic hormone. It keeps the ACTH(4-7) portion intact and replaces the native C-terminal residues with a Pro-Gly-Pro tripeptide. That single design choice is what separates Semax from the natural fragment.

Why does Semax have a Pro-Gly-Pro tail?

The Pro-Gly-Pro motif was added to make the molecule more resistant to the enzymes that normally break down short peptides. Proline residues are awkward substrates for many peptidases, so capping the C-terminus this way slows degradation and extends the peptide's measured half-life in research settings.

Is Semax an FDA-approved drug?

No. Semax is not approved by the U.S. FDA. It appears on the Russian Federation's list of essential medicines, but in the United States it is sold only as a research-use-only chemical and is not equivalent to any FDA-approved pharmaceutical product.

What does the name "Semax" mean?

The name derives from the Russian phrase for "seven amino acids," a nod to the fact that it is a heptapeptide. It was first described in the scientific literature in 1991 and developed within Russian research programs.

The Bottom Line

Strip Semax down and you're left with a simple, elegant idea: take the active front end of a natural hormone fragment, ACTH(4-7), and cap it with a Pro-Gly-Pro tail. That one edit buys resistance to enzymatic breakdown, shifts the molecule's measured potency, adds copper-binding chemistry through the histidine residue, and even leaves a meaningful fragment behind once the peptide degrades. It's a clean case study in fragment-based peptide design — proof that a small, well-chosen change at the end of a chain can ripple through every part of a molecule's behavior. If you're exploring how research peptides are built, Semax is a structure worth keeping in mind alongside the other compound explainers in our research library.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.